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The work aimed to study a new mucoadhesive prolonged release tablet containing 24 μg 
clobetasol-17 propionate (CP) suitable for the management of oral lichen planus. Low swellable 
dosage forms were designed by combining a mucoadhesive polymer, i.e. poly(sodium 
methacrylate, methylmethacrylate), with hydroxypropylmethylcellulose and MgCl2. This 
formulation was selected to modify the tablet erosion rate in order to obtain a release of CP over 
a 6 h period. A double-blind controlled study was performed using three groups of patient (n=16) 
which received 3 applications-a-day over 4 weeks of the developed CP tablets (group CP-T), 
placebo tablets (group CP-P) or commercial CP ointment for cutaneous application (123 
μg/application) extemporary mixed with OrabaseTM (group CP-O). At the end of the study, pain 
and ulceration resolved in 13/16 and 11/16 patients of group CP-T and group CP-O, respectively. 
In the group CP-O, a transient acute hyperaemic candidosis (n=2) and taste alteration (n=4) were 
also observed. No changes in clinical signs of partients in the group CP-P were evident. The 
application of mucoadhesive tablet containing 24 μg CP 3 times-a-day appeared to be effective, 




Oral lichen planus (OLP) is a rare chronic auto-immune muco-cutaneous inflammatory disease that may 
cause bilateral white striations, papules or plaques with or without erythema and ulceration involving any 
buccal mucosae [1, 2]. Symptoms range from none to painful oral lesions, affecting the quality of life. 
Current standard treatment is administered primarily, Since there is no established therapy, the current 
clinical treatment consists in the topical administration of high-potency topical corticosteroids, such as 
clobetasol propionate (CP) to control symptoms [3, 4]. Since buccal CP dosage forms are not 
commercially available the administration is made using semisolid preparations for skin application mixed 
with an adhesive paste, namely Orabase
TM
 [5-7]. This approach presents several drawbacks, including 
difficulties in applying the medication at various oral sites, taste alterations, limited contact time and 
possible swallowing of a formulation not designed for the buccal route. Therefore, to improve the patient’s 
compliance and reduce the risks of side effects, the development of a mucoadhesive solid dosage form 
could be of interest. Several mucoadhesive dosage forms, such as microparticles [8], patches [9] and 
tablets [10], could results suitable for the treatment of OLP. Nevertheless, considering that OLP is an 
orphan pathology, tablets obtained by direct compression could result advantageous because their 
production is easier and cheaper compared to the other two dosage forms.  
The present investigation aimed to evaluate the utility of a 24 μg CP mucoadhesive tablet based upon a 
poly(sodium methacrylate, methylmethacrylate) (PMM), a mucoadhesive no-swellable polymer [9]. A 
type of hydroxymethylcellulose was selected among a series of hydrocolloids on the bases of a 
preliminary screening, magnesium chloride was chosen because of its ability in reducing PMM erosion 
rate [11]. The formulative study was focused on in vitro characterization of tablets in order to define 
which formulation fulfilled desirable clinical characteristics. The criteria of acceptance were based on 
mucoadhesive properties, lack of swelling and drug release over a 6-hour period.  
The optimized formulation was tested in a double-blind, placebo-controlled study in individuals with OLP 




2. Materials and methods 
 
2.1 Formulation study 
2.1.1 Materials and Tablet preparation 
Clobetasol 17-propionate (CP) (SICOR, I), magnesium chloride (ACEF, I); Methocel

 K4M (HPMC 
K4M), substitution: methoxyl = 22%, hydroxypropoxyl = 8.1%, nominal viscosity 2% in water: 4000 cP 
(Colorcon, I); Eudragit

 S100, poly(methacrylic acid, methyl methacrylate), molar proportions of the 
monomer units 1:2, molecular weight  135,000 Daltons (Röhm, G); Crude (Type II) mucin from porcine 
stomach (Sigma Chemical Co., USA). PMM was obtained by adding 10% (w/w) NaOH aqueous solution 
to 15% (w/w) Eudragit
®
 S100 aqueous suspension, untill complete salification. The aqueous solution [9] 
was freeze-dried (EDWARDS Modulyo, USA) and the resulting powder was milled by an Ultra 
Centrifugal Mill (RETSCH ZM200, G) equipped with ring sieves of 0.25 mm. 
The composition of placebo and CP loaded tablets is shown in Table 1. Powders were mixed using a 
Turbula mixer (WAB Turbula, CH) for 10 min. Tablets (7 mm diameter and 80 mg weight) were prepared 
by direct compression using a single punch tablet press (Korsch, type EKO, G). The upper punch was set 
as to obtain tablets with a crushing resistance of about 7 Kp. The uniformity of CP content in mixtures and 
tablets was evaluated according to European Pharmacopoeia [12].  
 
2.1.2 ATR-FTIR spectroscopy 
About 15.0 mg sample was place on a ZnSe-crystal mounted in ATR cell (Perkin Elmer, USA). FTIR 
measurements were performed with Spectrum
TM
 One spectrophotometer (Perkin Elmer, USA). The 
spectra were recorded at 2 cm
–1
 resolution and 32 scans were collected over the wavenumber region 4000 
– 650 cm–1. The analyses were performed on raw polymers and hydrated swelling layers. Placebo tablet 
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was incubated in purified water and after 20 min the hydrated layer was carefully removed from the tablet 
and it was directly applied on the ATR accessory of the FTIR spectrometer. 
 
2.1.3 Swelling properties 
Swelling and erosion of PMM and the relative blends were evaluated by gravity method. Tablets of 80 mg 
were attached by cyanoacrylate glue to a glass plate and immersed in 30 ml of deionized water under 
constant stirring. At predetermined time intervals, polymeric tablets were removed from the beaker, 
rinsed, weighed and photographed. The variation (W) of tablet weight over time, namely water uptake 
and mass loss, was calculated according to the following equation: 
W = (Wt - Dt) / Dt         eq. 1 
where: 
- Wt = weight of wet tablets at the time t  
- Dt = initial weight of dry tablets at time t.  
 
2.1.4 Erosion rate 
Placebo compacts (250 mg, 13 mm diameter, Table 1) were prepared using a hydraulic press (RIIC 
hydraulic press, UK) with a compaction force of 10 tons and a holding time of 10 min. In order to expose 
a single face with constant area to the medium, all surfaces except one base were coated by partial 
immersion in 8% w/w cellulose acetate propionate solution in dichloromethane. The erosion rate of tablets 
was determined quantitatively by fixing the compact eccentrically under the paddle at the distance of 1.8 
cm from the rotating axis. 500 ml of deionised water at 37.0 ± 0.5 °C were used as dissolution medium 
and stirring speed was 100 rpm. The dissolved amounts were spectrophotometrically assayed at  = 213 
nm. Erosion rate (G) was determined from the slope, calculated by linear regression, of the curve obtained 
by plotting the dissolved amount of the copolymer per unit area (mg/cm
2
) versus time (min).  
 
 6 
2.1.5 In vitro mucoadhesive test  
The texture analysis was performed using a software-controlled dynamometer (AG/MCL, Acquati, I) with 
a 5 daN force cell as previously described [9], using mucin as the adherent substrate [13-15]. Briefly, flat 
faced placebo and CP loaded compacts (weight: 170 mg, diameter: 11.28 mm) were obtained by applying 
a compression force of 10 tons for 30 s by means of a hydraulic press (Glenrothes, UK). The testing 
material compacts were attached to the mobile steel punch by cyanoacrylate glue. Mucin compacts 
(weight: 130 mg, diameter: 11.28 mm) were obtained applying a compression force of 10 tons for 60 s. 
The mucin compact was attached by cyanoacrylate glue to a steel plate fixed at the bottom of the tensile 
apparatus and hydrated with 80 l deionized water upon 5 min to obtain a jelly surface layer. Upon 
making contact between the polymeric compact and the hydrated mucin, a constant force of 1.3 N was 
imposed for 360 s. The mucoadhesive performance was measured in terms of the force required to 
separate the bioadhesive compact from the mucin (maximum detachment force, MDF) upon an elongation 
of 10 mm at the constant rate of 0.1 mm/s. The area under the curve of the detachment force versus the 
elongation represents the work or energy (work of adhesion, WA) required detaching two compacts.  
The stainless steel punch was used as negative control and HPMC compacts as positive one. The results 
are expressed as mean ± standard deviation (n=4). 
 
2.1.6 Drug content assay 
The tablets were crushed in a mortar and the powder was suspended in 20 ml mobile phase (AcCN/H2O, 
50/50 v/v). The CP content was determined by the following HPLC method using HP1100 Chemstation 
(Hewlett Packard, USA). Chromatographic conditions. Analytical column: Waters Spherisorb ODS2 (4.6 
x 150mm, 3μm); mobile phase: AcCN/H2O (50/50 v/v); flow rate: 1.0 ml/min; wavelength set: 240 nm; 
injection volume: 20 l. The drug concentrations were determined from standard curves in the range of 
0.05-5 g/ml.  
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2.1.7 In vitro drug release 
Dissolution test was carried out in closed vials and stirred in a shaker incubator (50 strokes/min) at 
37±0.5 °C. The tablets were glued to the bottom of 5 ml vials containing 4 ml dissolution medium 
(deionized water). At each time point, the medium was completely withdrawn for analysis, diluted with 1 
ml acetonitrile and the amount of CP released was tested by HPLC (section 2.1.6). The withdrawn water 
was replaced with equal volumes of fresh medium.  
 
2.1. 8 In vivo mucoadhesion study 
The study was conducted in accordance with the ethical principles originating from the Declaration of 
Helsinki and followed the ICH-GCP guidelines of 17/01/1997, and was in compliance with local 
regulatory requirements. All subjects were completely informed concerning the pertinent details and the 
purpose of the study. A written consent form was completed by each subject prior to dispensing test 
materials. The study was conducted on 6 healthy human volunteers (aged 25-28 years) using 25 mg 
placebo tablets attached to upper buccal sulcus, in the canine fossa. Volunteers were allowed to drink 
during the study, while solid food and smoking were prohibited. Volunteers were asked to record the time 
of insertion and time at end of adhesion (permanence time), and any mucosal irritation or discomfort in 
mouth. 
 
2.1. 9 Statistical analyses 
Tests for significant differences between means were performed by Student t-test or one-way ANOVA by 
using the software SPSS 11 (Spss Inc., USA). Differences were considered significant at the p<0.05 level. 
 
2.2 Double-blind controlled clinical trial 
 
2.2.1 Subject.  
One investigator recruited subjects and evaluated the outcomes of therapy.  
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Inclusion criteria  
The diagnosis of OLP was made following the clinical and histological criteria defined by the World 
Health Organization (WHO) [16]. . Patients were observed in the Department of Oral Medicine of the 
Università degli Studi di Napoli Federico II for a minimum of three months before the beginning of the 
trial and presented clinical signs of OLP [17-18]. The diagnosis determined by clinical observance was 
confirmed by reviewing pre-treatment biopsies  samples taken within a week before the beginning of the 
trial as reported in section 2.2.3. A score system for signs of OLP was assigned on the basis of increasing 
severity and symptoms (Table 2). HCV + patients also were enrolled. 
Exclusion criteria. 
Patients who showed severely impaired renal or hepatic function, and women of childbearing age were 
excluded. Patients with a history of glaucoma were excluded. 
Based on these criteria, 48 Caucasian patients were enrolled in the study (26 women and 22 men, aged 32-
72 years, median 51.5 years).Each enrolled patient signed informed consent, and the procedures of this 
study were in accordance with the ethical standards on human experimentation (institutional and national) 
and with the Helsinki Declaration of 1975, as revised in 2000. Following informed consent the inclusion 
and exclusion criteria were confirmed. 
2.2.2 Randomizing protocol and study design 
The patients were assigned to 3 groups consisting of 16 subjects by the investigators.  
Treatment assignment was blind to the clinical investigator. Before randomization, a letter was assigned to 
a prearranged therapeutic protocol. This sequence of numbers was known only to another investigator who 
provided the study medications for each group.  
Patient of each group received the developed CP tablets (group CP-T), the corresponding placebo tablet 
(group CP-P) or CP semisolid preparation (123 μg/application) (group CP-O). CP tablets and placebo 
tablets were dispensed in identical white containers marked A and B. The CP semisolid preparation was 
prepared by using a commercial CP ointment for cutaneous application (Clobesol
®
, Shering Plough) 




Patients of each group received the products to apply three times a day over a 4 week period. 
Patients were instructed in how to place tablets in the canine fossa. Subjects of group CP-O were informed 
how to prepare and apply the ointment in Orabase
TM
. Patients were asked to record the length of the 
adhesion time of the tablet and potential side-effects. Subjects and the clinical investigator did not know 
the therapy to which they were assigned.  
At weekly visits during the four-week trial, the clinical investigator recorded the symptoms in a four-point 
descriptive-qualitative scale as follows: 0 = no evidence of disease; 1 = mild involvement; 2 = moderate 
involvement; 3 = severe involvement. All patients were monitored for adverse events and were evaluated 
for clinical signs and symptoms of candidiasis (white adherent patches, erythema and oral burning), the 
presence of moon face, hirsutism, fluid retention, and weight increase. Patients were tested for blood 
glucose levels and blood pressure. Patients were also interviewed to assess mood changes, gastrointestinal 
disorders, easy bruising and taste loss.  
2.2.3.Biopsy collection 
Biopsies (8 mm diameter tissue samples) were taken from all subjects within one week of the clinical trial, 
and two weeks following completion of treatment from the same region. All specimens were fixed in 
formalin 10% PBS buffer, embedded in paraffin and processed for haematoxylin-eosin staining. At time 0 
and after the therapy, 5 ml blood samples were collected by venipuncture, in oxalated vacutainers and 
centrifuged for cortisol levels.  
 
 
3. Results and discussion 
 
3.1 Formulation study 
3.1.1 Placebo tablets 
Upon contact with water, Tablets P1 made of the pure PMM rapidly hydrated and a slight increase in their 
size was observed within 10 min. Then, PMM started to erode with concomitant weight loss and the tablet 
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completely dissolved in about 90 min. Tablets P2 containing 10% w/w MgCl2 did not swell significantly 
and a decrease with time in tablet weight loss was measured. The addition of HPMC (Tablet P3) caused a 
significant increase in tablet weight and diameter which increased from 7 mm to 10.5 mm; afterwards, the 
tablet weight loss was similar to the formulation containing MgCl2 (Fig. 1). When the mixture of HPMC 
and MgCl2 was added to PMM (Tablet P4), the increase in tablet dimension due to hydration was closer to 
that of the pure PMM and its weight remained almost constant over 90 minutes. Moreover, the 
determination of the tablet erosion rate (G) evidenced that this formulation was the most effective in 
reducing the PMM dissolution (Table 1). 
In order to explain the differences observed in the tablet behaviour upon hydration, ATR-FTIR 
spectroscopy measurements were performed. After hydration of tablets, a band at 1645 cm
-1
 assigned to 
the symmetric stretch of the water molecules was clearly detectable in all the formulations. ATR-FTIR 
spectra of Tablet P1 made of the pure PMM (Fig. 2) showed the characteristic band of the C=O stretching 
vibration of the esteric group at about 1712 cm
-1
 and two bands at 1548 cm
–1
 and 1347 cm
–1
 corresponding 
to the anti-symmetrical a(COO-) and symmetrical s(COO-) vibration of the -COO- structure, 
respectively [19]. Moreover, the bands at 1249, 1197 and 1163 cm
-1
 arise mainly from stretching modes of 
the ester group [20]. 
The spectrum of hydrated HPMC showed two main bands at about 3370 cm
-1
 and 1640 cm
-1
 which were 
attributed to water (Fig. 2) and a broad band between 1200 and 900 cm
-1
 corresponding to C-O and CHx 
[21]. The latter peaks were not detected in Tablets P3 and P4 as they were masked behind the bands of 
PMM. Furthermore, in the case of Tablet P3 no shifts of the PMM bands were recorded (Fig. 2) 
suggesting the absence of interactions between the two materials. 
The spectra of the hydrated tablets containing MgCl2 were mainly characterized by changes in the bands 
of PMM ester groups. As already described, in the hydrated Tablets P2 the metal ion strongly interacted 
with the C=O and COO
-
 moieties of PMM [19] which led to a change in the charge distribution on the C-
O esteric vibration. Indeed, the bands attributed to the stretching vibrations of C-O-C moiety of the esteric 
group shifted towards higher wavenumbers (Fig. 2). When both MgCl2 and HPMC were present (Tablet 
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P4), changes involved (C-C-O) that significantly shifted towards higher wavenumbers (from 1249 to 
1260 cm
-1
). This data suggested that Mg
2+
 in the hydrated tablet caused a different distribution of the 
charge on the esteric group of PMM forming hydrogen bonds with HPMC. Such hypothesis was 
supported by the shift of (C-O-C) band towards lower wavenumbers with respect to those registered in 
the gel layer of Tablet P2. The interactions among PMM, Mg
2+
 and HPMC can reduce the ability of water 
to hydrate Tablet P4 causing a marked reduction of the tablet erosion rate and swelling.  
The mucoadhesive properties of the formulations are shown in Table 1. As already described, the 
presence of the MgCl2 (Tablet P2 and P3) caused a statistically significant decrease of the MDF of PMM 
(p<0.04) due to physical cross-linking of the copolymer. The formation of cross-links between the 
polymer chains did not allow them the freedom of movement and flexibility required for the penetration 
into the mucus gel network. Moreover, diffusion of water into the polymer network occurs at a lower rate 
resulting in decreased swelling of the polymer and a decreased rate of interpenetration between PMM and 
mucin. However, MDF and WA values were statistically higher than those registered with the negative 
control (MDF: 2.81±0.20 N; WA: 0.65±0.01 mJ).  
Information reported by volunteers of the panel test confirmed the in vitro data. The residence time was 
longest for tablets containing HPMC and MgCl2 (Table 1) and the volunteers described discomfort due to 
increased swelling only tablets made of both PMM and HPMC (Tablets P3). In all cases no mucosal 
irritation was reported. 
 
3.1.2 Drug loaded tablets 
As expected, the presence of CP in the polymer blends did not further modify both the tablet erosion rate 
and the in vitro mucoadhesive properties and texture profiles. The results showed that only for the Tablet 
F4, MDF and WA were significantly lower than those of the corresponding placebo blends (p<0.05). The 
non-interference of CP on mucoadhesive properties and erosion rate can be justified considering that the 
drug content was less than 0.025% and the drug, being a crystalline solid, does not modify the structure of 
Comment [FS1]: P? 
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the polymeric network. Indeed, the wavenumber and geometry of the main bands of the spectra recorded 
on the dry and hydrated CP loaded tablets overlapped with the corresponding spectra of placebo tablets 
(data not shown).  
The in vitro release of CP from the tablet made of pure PMM (Tablet F1) was complete in 90 min (Fig. 3) 
as predicted by the erosion rate of the polymer (Table 1). The addition of 10% w/w MgCl2 (Tablet F2) 
caused a decrease in drug release due to the cross-linking in polymer chains in presence of Mg
2+
. A 
similar release profile was evident when 10% w/w HPMC was added (tablet F3). As expected by the 
characterization of the placebo tablets, only the combination of 10% w/w MgCl2 and 10% w/w HPMC in 
formulation F4 resulted effective in prolonging CP release over a six hours period (Fig. 3). Possible 
explanation of the results could be the cross-linking of PMM chains in presence of magnesium ions, that 
might lower the mobility of water molecules entrapped into polymer network. In this case the drug release 
was delayed from Tablet F4 because of the formation of a highly viscous gel barrier of the entrapped 
HPMC that was effective in maintaining tablet cohesiveness. 
Since Tablet F4 could effectively control CP release over a 4-h period and the corresponding placebo 
tablets (Tablet P4) had an in vivo residence time of about 6 h, this formulation was selected for the clinical 
study. 
 
3.2 Clinical trial of OLP 
 
The patients enrolled in the groups CP-T and CP-P reported the excellent adhesion of the CP tablets in the 
buccal cavity with residence time averaging 4–6 h. The mucoadhesive tablets did not cause irritation or 
pain and the subjects reported the tablet tasted neutral or slightly salty.  
Data on the pre- and post-treatment evolution of OLP are displayed in Table 3 and Table 4. No patient 
dropouts occurred in the study. The histological findings showed a reduction of hyperkeratosis and 
acanthosis of the epithelium at the end of the treatment and a decrease of the band-like inflammatory 
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infiltrate in the samples from the groups CP-T and group CP-O, and no changes were seen in the placebo 
group (group CP-P). 
Blood cortisol levels, normally ranging from 5 to 25 µg/dl in the morning, were not statistically different 
among the three groups pre- (group CP-T: 6.8 µg/dl to 23.5 µg/dl; group CP-P: 4.5 µg/dl to 21.3 µg/dl; 
group CP-O: 8.1 µg/dl to 25 µg/dl) and post-treatment (group CP-T: 5.5 µg/dl to 19.5 µg/dl; group CP-P: 
5.9 µg/dl to 22.4 µg/dl; group CP-O: 5.1 µg/dl to 23 µg/dl), indicating limited systemic absorption of CP. 
No adverse effects related to the treatment were recorded, except for 2 episodes of transient acute 
erythematous candidosis during the last treatment week for two patients in group CP-O who were treated 
with with nystatin at the end of the trial. Taste loss was reported for 4 patients of the group CP-O. In the 
individuals of group CP-P, there was an increase in symptoms, as reported in Table 4.  
To assess the utility topical therapy of OLP, 16 patients with different clinical types of OLP (severe 
reticular, atrophic and erosive) were treated by applying mucoadhesive tablets containing a low dose of 
CP (24 µg/tablet) three times a day. 
At the end of the treatment period, oral pain and ulceration had resolved (complete response) in 13/16 
patients in group CP-T (Fig. 4) and 11/16 in the group CP-O with remission of atrophy and erosion and 
reticular lesions (score 0). There was no change in the group CP-P subjects (placebo tablets). 2/16 patients 
of the group CP-T and 3/16 of group CP-O showed score 1 for signs and symptoms and 1/16 of the group 
CP-T and 2/16 of the group CP-O reported score 2 for signs and 1 for symptoms.  
The results of this study showed that the use of low concentration CP in mucoadhesive tablets offers an 
efficacious treatment of different clinical types of OLP. 
Previous studies of topical steroid for management of oral mucosal disease have assessed drug delivery in 
non-sustained release forms. Lo Muzio et al. treated oral aphthous lesions and lichen planus by applying 
CP with a bioadhesive system with improvement in oral lesions [5]. Lozada-Nur et al. used CP mixed in 
an adhesive paste to treat patients with severe erosive disease of the oral mucosa, reporting a complete 
response in 62.5% of patients and an excellent response in 29.7%; they described the treatment as 
efficacious and safe [4]. Silverman et al. used 0.025% fluocinolone in Orabase
TM
 paste to treat patients 
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with erosive OLP. They concluded that the treatment was of some benefit to 61.9% (96/155) of the 
patients in their series, even though only 14.1% (22/155) of the patients were symptom-free [2]. Gonzalez-
Moles et al. have recently shown excellent outcomes in the treatment of severe erosive gingival lesions by 
topical application of CP in custom trays with 100% of success attributed to the improved delivery to all 
lesions through the use of the tray, the higher concentration used (0.05% vs. 0.025%), and the duration of 
contact between the drug and the lesion [22]. Nevertheless in this study a control group was not enrolled 
and 100,000 IU/cc of nystatin in paste was also administered because of the large surface area in contact 
with the drug, the high concentration of CP used and the occlusive nature of the tray method. 
Because OLP is chronic condition, treating the symptoms is extremely important in addressing quality-of-
life. This study aimed to increase the contact time to about 5 hours to allow a decrease in steroid 
concentration in order to reduce potential side-effects (i.e. candida infection) and improve the patients’ 
compliance. The mucoadhesive tablet did not cause side effects, cortisol levels in plasma were not altered, 
no findings of Candida infection was seen during the treatment and the administration of an anti-mycotic 
agent was not required. Moreover, there were no increases in blood pressure or episodes of 
hyperglycaemia among patients with a history of diabetes or controlled hypertension. 
In conclusion, HPMC and MgCl2 are effective in controlling PMM hydration/erosion and, consequently, 
drug release without significantly modifying mucoadhesion. Moreover, the lack of mucosal irritation and 
adverse effects confirmed the suitability of this combination to prepare mucoadhesive tablets. The 
application of 24 µg CP tablet may be an efficacious and safe treatment of OLP then semisolid preparation. 
This preliminary study suggests that this vehicle may have utility in the delivery of anti-inflammatory 
medications and other agents for treatment of oral conditions. 
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Fig. 1 – The swelling properties of the four tablet formulations over time. The mixture exhibited a 
different performance upon hydration depending on the tablet composition. When 10% (w/w) MgCl2 was 
added (-- and insert B) the pattern was comparable to that of pure PMM (-- and insert A): the tablets 
dissolved without swelling. Tablets containing 10 % (w/w) HPMC (--and insert C) or both MgCl2 and 
HPMC (-- and insert D) formed a slight swelling layer within the first 10 min followed by erosion.  
 
Fig. 2 – ATR-FTIR spectra of hydrated placebo formulations. 
 
Fig. 3 – Release (%) of CP from the buccoadhesive tablets made of the pure PMM (--), or mixing 10% 
w/w MgCl2 (--), or 10% w/w HPMC (--) or a mixture thereof (--). 
 
Fig. 4 - Reticular-erosive lichen planus before (a) and after (b) treatment with low concentration of CP in 
mucoadhesive tablets.  
 
Table 1. 
Composition of placebo (series P), CP loaded tablets (series F) and technological characterization. 
 
Form. 

















(min) CP PMM HPMC MgCl2 
P1 - 100 - - - 4.820±0.211 5.56±0.62 2.58±0.23 257±58 
P2 - 90 - 10 - 3.551±0.226 4.41±0.77 2.08±1.17 281±74 
P3 - 90 10 - - 3.107±0.214 4.42±1.63 2.28±0.75 288±86 
P4 - 80 10 10 - 1.579±0.196 3.25±0.11 1.26±0.10 330±34 
F1 0.03 100 - - 23±1 4.970±0.159 5.63±1.37 3.39±1.18 - 
F2 0.03 90 - 10 25±0 3.423±0.201 4.22±0.31 1.56±0.09 - 
F3 0.03 90 10 - 24±1 3.307±0.192 4.51±1.00 2.75±1.14 - 
F4 0.03 80 10 10 24±0 1.502±0.183 3.81±0.42 2.39±0.16 - 
* G100: erosion rate; § MDF: maximum detachment force; # WA: work of adhesion; † IVRT: in vivo residence time.
Tables
 Table 2.  
Signs and symptomatic scoring systems 
 
Sign Symptom score 
-  asymptomatic patients 0 
Reticular patients with mild symptoms that did not affect quality of life 1 
Atrophic 




severe symptoms that significantly interfered with patients’ quality of 
life 
3* 
* in the case of patients with intraoral manifestations of more than one type of OLP, the 
highest score was recorded.  
 
 
Table 3.  










start end start end start end 
Reticular 5 0 6 3 4 0 
Atrophic 3 1 3 3 2 1 
Erosive 4 0 5 5 5 2 
Mixed 4 2 2 2 5 2 
No signs 0 13 0 3 0 11 
Total 16 16 16 16 16 16 
 
 Table 4. 









start end start end start end 
absence of symptoms (0) 2 13 3 3 4 11 
mild symptoms (1) 5 2 8 7 6 3 
moderate symptoms (2) 6 1 4 4 5 2 
severe symptoms (3) 3 0 1 2 1 0 
Total 16 16 16 16 16 16 
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